国内の医療環境では、高齢化や医療費の増加が懸念されており、医療費を抑える有効な手段として後発医薬品の利用があります。

厚生労働省は、医療費の抑制や患者への負担軽減を図るために後発医薬品の普及を支援しています。

公衆衛生の観点からも、個々の患者の治療だけでなく、社会全体の健康を考えなければなりません。

医療資源を効果的に活用し、多くの患者に適切な治療を提供するために、低価格の薬剤を選択することは必要です。

一方で特許切れによる後発医薬品の登場は、先発医薬品メーカーの業績悪化の大きな要因となります。

後発医薬品の積極的な使用は、医療費削減や健康保険制度の枠組み、規制の整備など、多くの要因が絡み合っています。

社会的責任が高い製薬企業としての立場と、自由競争のもと、民間企業として経営に対するあらゆる自己責任を担うべき存在としての立場から、今後も持続的な成長を続けるための最適解を見つける必要がありそうです。

“Reasons for Choosing Low-Priced Products: Perspectives from Government and Healthcare Professionals”

In the domestic healthcare landscape, concerns over aging populations and rising medical expenses have prompted the utilization of generic pharmaceuticals as an effective means to control healthcare costs.

The Ministry of Health, Labour and Welfare supports the proliferation of generic pharmaceuticals to mitigate healthcare expenses and alleviate the burden on patients.

From a public health standpoint, considerations extend beyond individual patient care to encompass the overall health of society.

To efficiently allocate medical resources and provide suitable treatments to a broader patient base, opting for low-priced pharmaceuticals becomes imperative.

On the other hand, the emergence of generic pharmaceuticals due to patent expirations significantly contributes to the decline in the performance of originator pharmaceutical manufacturers.

The proactive utilization of generic pharmaceuticals intertwines various factors, including healthcare cost reduction, the framework of health insurance systems, and regulatory enhancements.

Balancing the position of socially responsible pharmaceutical companies with the role of assuming full accountability for management as private entities operating within a framework of free competition seems crucial for sustaining continuous growth moving forward.